Impact of Vitamin D Supplementation in Patients With Multiple Sclerosis
Status:
Completed
Trial end date:
2018-04-30
Target enrollment:
Participant gender:
Summary
Vitamin D is important risk factor for developing multiple sclerosis (MS) and for disease
progression. Patients with MS who had lower vitamin D levels were at increased risk for more
clinical attacks and faster disease progression. It was also shown that patients with MS had
lower vitamin D levels in serum than healthy controls. It is not clearly defined, which are
the levels of vitamin D in serum, that are high enough to trigger immunomodulatory effect and
are safe for patients.
This double-blind randomized clinical trial was designed to compare impact of vitamin D
supplementation in two different doses (1000 IU/day vs 4000 IU/day) in patients with
relapsing remitting MS. The main goal of this trial is to compare dose response on vitamin D
supplementation and to estimate more closely appropriate level of vitamin D in serum which
triggers some of experimentally shown immunomodulatory actions.